SET
- 产品代码
- SET
- 器械名称
- Immunoassay Blood Test For Amyloid Pathology Assessment
- 管理类别
- 第 2 类(Class II)
- 21 CFR 条款
- 21 CFR 866.5840
- FDA 专业组
- Immunology
- 上市路径
- 需提交 510(k) 上市前通告
- 该代码近三年的 510(k)
- 4 件
- 其中 Summary 已存档
- 4 份,可直接下载
- FDA 历史累计 510(k)
- 4 件(全部年份;本站只收录近三年的明细)
FDA 分类定义
An Immunoassay blood test for amyloid pathology assessment is an in vitro diagnostic test used to identify patients with amyloid pathology associated with Alzheimers Disease who have signs and symptoms of cognitive decline. The results of the test are to be interpreted in conjunction with other patient clinical information.
该代码近三年的 510(k)(4 件)
| 510(k) 号 | 批准日期 | 申请人 | 器械名称 | 摘要 |
|---|---|---|---|---|
| K261686 | 2026-08-19 | Roche Diagnostics | Elecsys Phospho-Tau (217P) Plasma | |
| K253240 | 2026-08-19 | C2N Diagnostics, LLC | PrecivityAD2 Test | |
| K252163 | 2025-10-08 | Roche Diagnostics | Elecsys Phospho-Tau (181P) Plasma | |
| K242706 | 2025-05-16 | Fujirebio Diagnostics,Inc. | Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio |
FDA 官方分类页: SET
分类与上市路径以 FDA 现行公告为准。本页数据来自 openFDA(CC0 公有领域),不构成注册策略建议。